brentuximab vedotin
seagen
['lymsm', 'cml']
wide awake at 0330 (darn time change!), so might as well tweet some #17icml abstracts i found.
1) : better qol outcomes in pediatric chl during bv-based vs standard induction. 2-yr qol after bv better than healthy controls! #lymsm
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈